Drug Delivery Strategies For Oral Pediatric and Geriatric Products
Posted on October 6, 2014
By: Carsten Timpe, Team Leader Formulation, Sr. Principal Scientist
Angela Dischinger, Formulation Scientist
F. Hoffmann La Roche, Basel (Switzerland)
Introduction The paradigm of past decades in pharmaceutical industry was mainly to focus on development of blockbuster drugs that fit to all kinds of different patients, independent from their ages, physiological and disease conditions, genetic differences. It took many decades from the early days o...
To read the full article and other articles in this issue, please register for a free account or log in.
We will not sell or give your information to a third party. See our Privacy Policy
Related Topics and Keywords
API, B-cyclodextrins, bioavailability, co-processed mannitol, Compressed ODT's, Cyclodextrins, Dose-sipping technology, drug delivery, electronic tongues, excipient. taste masking, Geriatric, Heat-pressed ODT's, HME, Hot melt extrusion, lipid, Lipids, lyophilised, lyophilised ODT's, minitablets, Multiparticulates, ODT, oral disintegrating tablets, paediatric, palatability, pediatric, swallowability, sweetners, transdermal drug delivery
Related Products
Catalent Pharma SolutionsSubscribe to our FREE newsletter and WEBINAR UPDATES
We will not sell or give your information to a third party. See our Privacy Policy
